Clinical Trial

Sympathetic Mapping/ Ablation of Renal Nerves Trial

Study acronym: SMART
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
To evaluate the safety and efficacy of targeted renal sympathetic denervation using SyMapCath I® and SYMPIONEER S1® Stimulator/ Generator in patients with essential hypertension for at least 6 months of the disease history and pharmacotherapy, however, their blood pressure still cannot be controlled, then after standardized antihypertensive drug therapy (at least two drugs) for at least 28 days, office systolic blood pressure is still ≥ 150mmHg, ≤180mmHg.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2016-05-03; most recent amendment 2023-07-31.
Status change: Completed → Active, Not Recruiting 2023-07-31
Status change: Active, Not Recruiting → Completed 2023-04-11
Status change: Recruiting → Active, Not Recruiting 2022-02-28
Status change: Not Yet Recruiting → Recruiting 2016-09-30
Trial Details
NCT Number NCT02761811
Lead Sponsor SyMap Medical (Suzhou), Ltd.
Collaborators: Tigermed Consulting Co., Ltd
Conditions Hypertension
Enrollment 220 participants
Start Date 2016-06-30
Primary Completion 2022-08-25 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-08-02